Yep agree with this, and options will be available at .001.
However they have a lot going for them not just the FDA, so I actually agree with earlier post that Ilumen is their strongest and closest revenue... and they should give us some contracts in the next few weeks/months.
Then next year is the big one with medbridge... if they get de novo it will be absolutely game changing.
Ann: FDA Strategy and Regulatory Update, page-545
-
- There are more pages in this discussion • 148 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
